JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

ORAI1, FGF23, PP13, palladin, and supervillin as potential biomarkers in late-onset pre-eclampsia: a comparative study in maternal and cord blood

  • 0Department of Obstetrics and Gynecology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Bmc Pregnancy and Childbirth +

|

July 24, 2025

|

July 24, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Pre-eclampsia biomarkers ORAI1 and FGF23 show altered levels in maternal and cord blood, aiding diagnosis. Combined ORAI1 and FGF23 measurements improve diagnostic accuracy for this pregnancy disorder.

Area Of Science

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Biomarker Discovery

Background

  • Pre-eclampsia poses a significant global health challenge due to its complex pathophysiology.
  • Identifying novel biomarkers is crucial for understanding, diagnosing, and managing this pregnancy-specific disorder.
  • This study investigated Calcium Release-Activated Calcium Channel Protein 1 (ORAI1), Fibroblast Growth Factor 23 (FGF23), and Placental Protein 13 (PP13) as potential biomarkers for late-onset pre-eclampsia.

Purpose Of The Study

  • To investigate the differential expression of ORAI1, FGF23, and PP13 in maternal and umbilical cord blood.
  • To assess their potential as biomarkers for late-onset pre-eclampsia.
  • To explore maternal-fetal protein transfer dynamics in pre-eclamptic conditions.

Main Methods

  • A cross-sectional, case-control study involving 61 women with late-onset pre-eclampsia and 61 normotensive pregnant women.
  • Maternal and umbilical cord blood samples were collected immediately before and after cesarean delivery, respectively.
  • Protein concentrations were measured using enzyme-linked immunosorbent assay (ELISA).

Main Results

  • Maternal and cord blood ORAI1 concentrations were significantly elevated in pre-eclampsia.
  • FGF23 and PP13 levels were significantly decreased in maternal blood.
  • Combined ORAI1 and FGF23 assessment demonstrated enhanced diagnostic performance (AUC = 0.782), with ORAI1 showing the highest individual accuracy (AUC = 0.733).

Conclusions

  • Altered expression of ORAI1, FGF23, and PP13 indicates disruptions in calcium signaling, phosphate metabolism, and placental function in late-onset pre-eclampsia.
  • Parallel measurement in maternal and cord blood offers unique insights into maternal-fetal interface dysfunction.
  • A multi-marker approach, particularly combining ORAI1 and FGF23, is valuable for capturing pre-eclampsia's complexity and improving diagnostic strategies.

Keywords: